Labiotech.eu

Interview 14 Feb 2018

This Biotech Veteran Is Using These Tips for Successful Drug Development, Here Is Why

Our second interview at Refresh in Vienna was with Peter Llewellyn-Davies, the founder of Accellerate Partners and Apeiron’s CFO and CBO. He told us how he found himself at the biotech and shared the lessons he learned on his way there. Peter Llewellyn-Davies founded Accellerate Partners in 2012, which offers services including corporate expansion, funding […]

February 14, 2018 - 5 minutesmins - By Alex Dale

antibiotic resistance phase III allecra 1

News and Trends 14 Feb 2018

Anti-Antibiotic Resistance Technology Gets Fast-Tracked to Phase III

Allecra Therapeutics’ candidate that blocks the development of antibiotic resistance has been awarded the FDA’s Fast Track Designation and will enter Phase III this summer. Allecra Therapeutics, our biotech of the week a few weeks ago, develops new treatments for multidrug-resistant Gram-negative bacterial infections. The company has received Fast Track Designation from the FDA and will begin […]

February 14, 2018 - 2 minutesmins - By Alex Dale

bicycle therapeutics solid tumors trial 1

News and Trends 14 Feb 2018

Bicycle’s First Peptide-Toxin Conjugate Enters the Clinic for Solid Tumors

A collaboration between Bicycle Therapeutics and Cancer Research UK has yielded its first peptide to enter clinical trials for solid tumors. Bicycle Therapeutics, the pioneer of the bicyclic peptide platform, has dosed the first patient in a Phase I/IIa trial with its solid tumors candidate, BT1718. The study will test the drug’s safety and efficacy in […]

February 14, 2018 - 3 minutesmins - By Alex Dale

artificial intelligence peptides nuritas 1

News and Trends 14 Feb 2018

Nestlé and AI Biotech Hunt Down Bioactive Peptides in Our Food

Nuritas and Nestlé will use artificial intelligence to find bioactive peptides in the food we eat for applications including diabetes, anti-aging, and animal and plant health. Nuritas wants to revolutionize the discovery of natural active ingredients that can support and improve human health. The company uses artificial intelligence (AI) to look closely at the foods we […]

February 14, 2018 - 3 minutesmins - By Alex Dale

blindness deafness usher syndrome proqr2 1

News and Trends 13 Feb 2018

ProQR Tackles Blindness Caused by a Rare Genetic Disease

ProQR has received €6M from the American charity, Foundation Fighting Blindness, for the development of its treatment for Usher Syndrome – the leading cause of combined blindness and deafness. ProQR focuses on the development of RNA-based medicines for genetic diseases like cystic fibrosis. However, it is the company’s program targeting Usher syndrome, the leading cause of combined […]

February 13, 2018 - 3 minutesmins - By Alex Dale

News and Trends 13 Feb 2018

Watch Out Eli Lilly: Novo’s Diabetes Drug Ozempic Gets European Approval

Update (13/02/2018): The European Commission has given Novo Nordisk a market authorization for Ozempic (semaglutide), bringing the competition for Eli Lilly’s Trulicity over to Europe. Eli Lilly executives have said that they are not worried by Novo’s competition, and keep confident on the performance of Trulicity, which now tops 40% of the market share of diabetes drugs belonging […]

February 13, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 13 Feb 2018

Erytech’s ‘Armed’ Red Blood Cells Will be Tested Against Triple Negative Breast Cancer

Erytech will test its Graspa technology for the treatment of a second solid tumor indication, breast cancer, following its success in pancreatic cancer. French biotech Erytech has developed an exciting platform for the treatment of cancer called Graspa, which encapsulates L-asparaginase in red blood cells. The company is now organizing a Phase II study for its next disease […]

February 13, 2018 - 2 minutesmins - By Alex Dale

fast wound healing prevents infection2 1

News and Trends 13 Feb 2018

High-Speed Healing Could Prevent the Infection of Chronic Wounds

Swedish scientists have used bacteria to deliver a chemical into wounds that speeds up the healing process. This could help to prevent their infection with dangerous strains of resistant bacteria. Researchers at Uppsala University have identified a technique to accelerate the wound healing process and reduce the chance of infection. The study, published in PNAS, […]

February 13, 2018 - 3 minutesmins - By Alex Dale

News and Trends 12 Feb 2018

No Nonsense Boehringer Ingelheim Jettisons Failing Alzheimer’s Disease Drug

Boehringer Ingelheim has ditched its Alzheimer’s drug after it failed to meet the endpoints of a Phase II trial but will continue to look at it for the treatment of schizophrenia. One of Germany’s biggest pharma companies, Boehringer Ingelheim, has given up on the development of its Alzheimer’s drug, BI 409306, which underwent Phase II testing. The […]

February 12, 2018 - 3 minutesmins - By Alex Dale

News and Trends 12 Feb 2018

Healthcare-Biotech Partnership Pledges to Take its Type 2 Diabetes Treatment Worldwide

Swiss pharma Roivant has given French biotech Poxel €28M upfront to get involved with the development and commercialization of imeglimin, a new treatment for metabolic disorders like type 2 diabetes. Poxel uses its expertise in metabolism to develop drugs for the treatment of disorders like type 2 diabetes. Its candidate imeglimin has caught the eye of […]

February 12, 2018 - 3 minutesmins - By Alex Dale

News and Trends 12 Feb 2018

First Functioning Kidney Tissue Generated from Embryonic Stem Cells

Researchers at the University of Manchester have used embryonic stem cells to produce kidney tissue that can filter the blood to produce urine, which opens the door to personalized kidney transplants. Scientists at the University of Manchester have generated human kidney tissue from embryonic stem cells for the first time. The research, published in the journal Stem […]

February 12, 2018 - 3 minutesmins - By Alex Dale

Interview 12 Feb 2018

MorphoSys’ CEO Tells Us What’s Next for Europe’s Antibody Expert

After 25 years, MorphoSys finally got over the line in 2017 with the FDA approval of its first antibody. CEO Simon Moroney tells us how the company hopes to build on its recent success. It may have started out as a tech provider, but MorphoSys now stands as one of the leading German biotechs, specializing […]

February 12, 2018 - 8 minutesmins - By Alex Dale

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

This Biotech Veteran Is Using These Tips for Successful Drug Development, Here Is Why

Anti-Antibiotic Resistance Technology Gets Fast-Tracked to Phase III

Bicycle’s First Peptide-Toxin Conjugate Enters the Clinic for Solid Tumors

Nestlé and AI Biotech Hunt Down Bioactive Peptides in Our Food

ProQR Tackles Blindness Caused by a Rare Genetic Disease

Watch Out Eli Lilly: Novo’s Diabetes Drug Ozempic Gets European Approval

Erytech’s ‘Armed’ Red Blood Cells Will be Tested Against Triple Negative Breast Cancer

High-Speed Healing Could Prevent the Infection of Chronic Wounds

No Nonsense Boehringer Ingelheim Jettisons Failing Alzheimer’s Disease Drug

Healthcare-Biotech Partnership Pledges to Take its Type 2 Diabetes Treatment Worldwide

First Functioning Kidney Tissue Generated from Embryonic Stem Cells

MorphoSys’ CEO Tells Us What’s Next for Europe’s Antibody Expert

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!